DuoGenic StemCells corporation

TPEX:7607 Stock Report

Market Cap: NT$841.7m

DuoGenic StemCells Valuation

Is 7607 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7607 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7607's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7607's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7607?

Key metric: As 7607 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 7607. This is calculated by dividing 7607's market cap by their current book value.
What is 7607's PB Ratio?
PB Ration/a
BookNT$0
Market CapNT$841.74m

Price to Book Ratio vs Peers

How does 7607's PB Ratio compare to its peers?

The above table shows the PB ratio for 7607 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.6x
6662 BioLASCO Taiwan
2.1xn/aNT$916.9m
6661 Welgene BiotechLtd
2xn/aNT$567.5m
4133 Abnova (Taiwan)
1.4xn/aNT$1.7b
6848 RBC Bioscience
1xn/aNT$247.8m
7607 DuoGenic StemCells
n/an/aNT$841.7m

Price-To-Book vs Peers: Insufficient data to calculate 7607's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Book Ratio vs Industry

How does 7607's PB Ratio compare vs other companies in the Asian Life Sciences Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
7607 is unprofitableIndustry Avg. 2.3xNo. of Companies13PB01.63.24.86.48+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: Insufficient data to calculate 7607's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is 7607's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7607 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 7607's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies